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ABSTRACT
The study of magnetoelectric (ME) nanomaterials has drawn significant interest due to their
novel physical, chemical and mechanical properties. The ME composites, typically made by
embedding a magnetic substance in a piezoelectric material, exhibit an ME effect described by
a magnetic-to-electrical signal conversion via an elastic interaction. The ME output voltage
determines the practicability of the composite for technological applications and biomedical
applications.
Polymer-based ME composites are emerging due to their ease of fabrication, flexibility
and high ME output voltages achieved to date. Furthermore, ME composites are envisaged to
function as contactless, dispersible electrodes that have potential for remote control of electrical
stimulation, sensing or release of drugs in biomedical applications. However, only ceramic ME
composites are recorded in biomedical applications to date.
Therefore, the aim of the project was to develop, characterize and apply the mechanism
of magnetic-to-electrical conversion using polymer-based ME nanocomposites, specifically for
the application of remotely activated drug release. The biodegradable piezoelectric polymer,
Polylactic Acid (PLA), was used to synthesize polymer microspheres containing magnetic
CoFe2O4 nanoparticles and characterization of their magnetic and piezoelectric properties was
undertaken. A key finding was demonstration of controlling the release of drugs (the antiinflammatory drug, Dexamethasone) from the ME polymer microspheres via a remotely
applied magnetic field. While the ME mechanisms affecting the drug release remain unclear,
several possible theories are discussed.
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1.1

Literature Review & Introduction

Magnetoelectric Materials and the Magnetoelectric Effect

The early research in ME materials preliminary focused on the single-phase ME materials that
exhibit both ferroelectric and ferromagnetic properties within the same compound (1, 2). This
was preliminary found with Cr2O3 (3). However, further discovery of ME crystals was
relatively slow until understanding the principles behind coexistence of magnetic and electric
coupling in Oxides (4). With the theoretical finding of coupling of magnetic and electric, later
several single-phase ME materials were discovered. For example, Bismuth-based compounds
(BiMnO3, BiFeO3), perovskites and Rare Earth (RE) materials such as REMnO3 compounds
(RE= Y, Ho, Er, Yb) (1). However, these materials are rare and have low permittivity and
permeability. These compounds are classified into two types, type 1 and type 2, based on the
origin of their multiferroicity. For type 1 compounds, the ferroelectricity and ferromagnetism
originate from two different sources which are independent from one another, whereas in type
2 compounds the magnetism determines the multiferroicity (2). Because of the independent
origin of multiferroicity in these single-phase materials, they exhibit very small ME
coefficients, 1-20 mV/cm Oe (5). Besides that, only a few single-phase compounds exhibit an
ME response at room temperature. For instance, Bismuth ferrite exhibits ME effect at room
temperature (6). However, single-phase ME materials are not desirable for the short term
applications because of their low magnetoelectric coefficient values, that are not be able to
detected (7). Due to the above limitations associated with the single-phase ME materials, the
ME composites have been developed (5).
The ferromagnetism of Magnetoelectric (ME) materials are associated with the
unpaired electrons in d or f shells while a vacant d shell generates ferroelectricity (8, 9). The
ME effect of these ME materials has drawn significant research attention recently (10). The
1

application of an external magnetic field to these materials changes the electric polarization of
the material, and is known as the ME effect. Similarly, the reverse ME effect is where a change
in magnetization can be generated by an altering an electric field (11).
ME composites can be fabricated by combining both ferroelectric materials/
piezoelectric polymers and ferromagnetic magnetostrictive materials together. BaTiO3,
PbTiO3, Pb (Zr,Ti)O3, BiFeO3 and Poly vinylidene fluoride (PVDF) are examples for common
ferroelectric and piezoelectric materials, whereas CoFe2O4 (CFO), NiFe2O4 (NFO), Fe3O4 are
widely used ferromagnetic materials (10). Though the ME composites demonstrate an ME
effect, each phase separately does not exhibit the ME effect. The following schematic diagram
(Figure1.1) illustrates the direct and reverse ME effect (2).

Figure 1.1-Illustration of a) direct and b) reverse ME effect generation (10).

2

When an external magnetic field is applied to the magnetic phase of the ME material,
a magneto strictive strain is induced which is then transferred to the piezoelectric phase,
causing polarization of the material (piezoelectric effect) (Figure 1.1a). This is referred as the
direct ME effect, which can be described by eq.1 (11). Similarly, an external electric stimulus
can induced strain on the piezoelectric phase (inverse piezoelectric effect) that is then
transferred to the magnetic phase, causing a change in the magnetization (Figure 1.1b and eq.2)
(10, 11).

Magnetic

eq. 1 Direct ME effect = Mechanical ×

Mechanical

Electric

Electric

eq. 2 Reverse ME effect = Mechanical ×

Mechanical
Magnetic

ME composites exhibit significantly higher output voltages or ME coefficients compared to
single-phase ME materials. Importantly, these ME effects can also be seen in higher
temperatures above room temperature (2).
The ME effect can be measured using three direct methods: static, quasi-static and
dynamic method. In the static method, the ME signal is measured with the increasing magnetic
field. During the measurement, the accumulated charges at the grain boundaries are transferred
to the electrodes, generating an error in the ME output voltage (12). The second technique,
quasi-static method, measures the ME signal as a function of time with the changing DC
magnetic field. However, the technique still cannot resolve the issue of charge accumulation
(13). Thus, the dynamic method (Figure 1.2) has been developed to overcome the above
problem by using a lock-in technique. Also, the lock-in technique only measures on a specific
frequency, that generates low-noise measurements. In this method, both AC and DC magnetic
fields are applied simultaneously and the ME response is measured as a function of DC
magnetic field (13).
3

The generated ME output of ME material is expressed using ME coefficient (αME), which is
denoted as:
eq. 3

∝ 𝑀𝐸 =

V𝑀𝐸
𝑇 × 𝐻𝑎𝑐

VME is the actual voltage output monitored by the lock-in amplifier, T is the thickness of
ferroelectric/PE phase and Hac is the strength of ac magnetic field (14).

Figure 1.2-Schematic Illustration of the experimental set up for dynamic ME measurement which
comprises with electromagnets for the application of DC magnetic field, Helmholtz coils for generating
AC magnetic field, Hallotron/Hall probe is a sensor to measure the actual value of DC magnetic field
and lock-in amplifier for ME response recording (15).

1.2

Bulk ME Composites

Although the ME property was first discovered in 1972, the field went dormant until the early
1990s primarily due to practical limitations in the low ME response. The year 2001 was a major
step in the development of ME laminate composites containing magnetostrictive (MS) alloy,
Tb1-x DyxFe2 (Terfenol-D), that later incorporated with piezoelectric materials of PZT, Poly
vinylidene fluoride and its copolymer Poly(vinylidene fluoride-trifluoroethylene) (16). Dong
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et al. (17-19) reported ME composites incorporating Terfenol-D with PZT and Mori et al. (20)
reported Terfenol-D/Poly vinylidene fluoride ME composites, that generate higher ME outputs
larger than 1 V/cm Oe.
Generally, the ME composites have three common geometric patterns, including
particulate composites (Figure1.3a), laminates (Figure1.3b) and fibers (Figure1.3c). These
structures are denoted as 0-3 (a), 2-2 (b) and 1-3 (c) structures, respectively.

Figure 1.3-Illustration of connectivity patterns in ME composites: (a) particulate composites, (b)
laminates (c) fibers (d) 0-2 type and (e) 0-0 type nanostructures (f) multiferroic/ferroelectric/magnetic
nanoring (21).

More recently, a number of novel geometric pattern nanostructures (22-25) such as 00 and 0-2 type have been demonstrated (21). The 0-0 type nanostructures contain epitaxial
ferroelectric and ferromagnetic nanodot arrays (Figure 1.3 e) that are reported to increase ME
coupling over other nanopatterned structures by tolerating the mechanical coupling at atomic
level (21).
0-3 structures are constructed by embedding magnetic particles within a ferroelectric
matrix and the ME effect of the composites strongly depends on the magnitude of the magnetic
5

field (10). There are several methods used to synthesize 0-3 particulate composites such as
sol-gel and spin coating (26). These composites however have a major drawback of current
leakage that occurs via the movement of dispersed magnetic particles through the matrix that
allows current to pass through. Recently, sintering techniques were introduced to increase the
ME coefficient of 0-3 composites, with values in the range of 10-100mV/cm Oe. This is
because the sintering techniques permit high density packing interactions among particles and
concurrently reduce the porosity of the matrix (10, 16, 27).
2-2 laminate structures are developed using alternating ferroelectric and magnetic
layers. These laminates can be fabricated into different shapes, such as discs, squares,
rectangles and rings (28). Such laminate structures eliminate the current leakage problem of
the 0-3 structures (10). Furthermore, the strong interfacial bonding between layers in ME
laminates enables effective strain transfer to generate large ME responses (26). The
conductivity of ferrite layers in these laminate structures is not sufficient to act as a conductive
electrode, which eventually weakens the ME output signal (26, 27). Therefore, an additional
metal film of Ag or Ni is used to improve the ME signal.
In contrast to particulate composites, the ME signal of the laminates depend on the
measurement direction. Thus, the ME coefficient of laminates can be measured in three ways
with respect to the magnetic field direction; transverse, longitudinal and in-plane longitudinal
(Figure 1.4) (16). Srinivasan et al. (29-31) using PZT combined with Nickle ferrite (NFO)
experimentally found that the transverse ME effect was higher than the longitudinal effect.

6

Figure 1.4-Schematic represents of the a) transverse-direction of thickness and b) longitudinaldirection of the length, ME measurement directions (32).

In 1-3 structures, magnetic fibers are incorporated into a ferroelectric matrix, PZT (16). A
higher ME coupling can be observed in these 1-3 structures due to the 1) effective coupling
promoted by the large interfacial surface area and 2) reduction of the substrate clamping effect
(26). However, ME coefficients cannot be directly obtained because of the current leakage
problem.

1.3 Polymeric ME Composites
Many of the above ceramic-based composites are expensive and fragile and as such they are
not widely used for practical applications. Therefore, polymer-based ME composites have
gained significant attention due to their reusable, flexibility and fabrication into a variety of
forms and shapes (27). Consequently, they can be used for various applications, for example
CFO/PVDF microspheres are used in biomedical, sensing, actuation, catalysis and energy
fields (33-35). The polymer shell avoids the particle-particle aggregation by inhibiting
interactions of the magnetic core, which ultimately increase the dispersion of nanoparticles (36,
37).

7

The polymer-based ME composites are mainly available in three different types,
particulates, laminates and polymeric binding structures (11), illustrated in Figure 1.5.

Figure 1.5-Illustration of three common polymeric composite types; a) particulates b) laminates and c)
polymer as a binder composite.

1.3.1 Particulates
Only a small number of polymeric particulates have described (27), comprising ferromagnetic
nanoparticles embedded in a piezoelectric polymer matrix. PVDF and polyurethane (PU)
piezoelectric polymers are commonly used in these types of ME composites (11). PU-based
ME composites; PU/Fe3O4 and PU/Nickel, can exhibit ME coefficients of >10 mV/cm Oe, with
the response unexpectedly showing no dependence on the magnetic properties of the magnetic
constituent (11, 37). Ma et al. (27) reported that the ME coupling is mainly caused by the
elasticity of the polyurethane. However, still the coupling of these compounds is not well
understood.
When considering PVDF based composites, magnetic NFO and CFO nanoparticles
embedded in P(VDF-TrFE) copolymer matrix demonstrated ME responses of 40 and 41.3
mV/cm Oe respectively (5, 38). However, the ME response of PVDF based composites depend
on the magnetic particles (38, 39).

8

1.3.2 Laminates
Laminate ME composites were developed to address the leakage current problem in bulk
nanocomposites. In addition, electrical polling of the piezoelectric phase enhances the ME
coupling in these composites (11). Different approaches used to fabricate laminate composites
have been reported. Cai et al. (40) developed laminates incorporating Terfenol-D/PVDF film
sandwiched between two PZT-PVDF films. The maximum ME coefficient for the composites
was reported to be 80 mV/cm Oe. The ME coefficient could reach 3V/cm Oe by increasing the
frequency of the laminates up to 100 KHz (41). In contrast, Lin et al. (42) constructed laminates
inserting PZT-PVDF within Terfenol-D/PVDF films and obtained a very high ME coefficient
of 6V/ cm Oe. The ME signal is dependent on the applied DC voltage in above structures (43).
The laminates constructed using Metglas and PVDF (Figure 1.6) to date produce the
highest ME output of 238 and 310 V/cm Oe for unimorph and three-layer structures
respectively. The higher effective piezomagnetic coefficient (d33) in metglas compared to
Terfenol-D makes Metglas /PVDF laminates more sensitive towards the applied magnetic field
(44).

Figure 1.6-Metglas and PVDF a) unimorph and b) three-layer laminates

1.3.3 Other Structures
In these structures (Figure 1.5c), both magnetic and piezoelectric particles are deposited within
a polymer matrix that acts as a binder. This type of ME composite was first made by dispersing
Terfenol-D nanoparticles within a PZT and PVDF polymer mixture, The maximum ME
9

coefficient value obtained for these structures was 42 mV/cm Oe (45), with the value depending
on the amount of Terfenol-D. To enhance the ME coupling, surfactants have been used. Chau
et al. (46) reported similar structures constructed incorporating, Terfenol-D, PZT with
Polyethylene, that exhibits ME coefficients of 1.3 mV/cm Oe.

1.4 Factors Affecting ME Effect in Composites
A good ME response can be obtained when there is strong coupling between the
magnetostrictive and piezoelectric components. The coupling depends on the connectivity
pattern and interface bonding of two constituents that facilitates effective strain transfer (47)
The 0-3 particulate and 1-3 fiber composites are either randomly dispersed or periodically
aligned (48), exhibiting lower ME responses compared to laminates (2-2 connectivity) that
have strong mechanical bonding between two phases at the interface. The dispersion of
magnetic nanoparticles in a larger surface area within a piezoelectric matrix has shown higher
ME response in 0-3 particulate composites. McDannaled et al. (28) experimentally showed that
PZT-CFO nanocomposites have a higher ME coefficient at lower CFO concentration. In
contrast, lower ME coefficients were obtained at higher CFO concentration due to particle
agglomeration.
Generally, a higher ME response can be obtained when a constituent of higher
piezoelectricity (PVDF, P(VDF-TrFE) and PZT) is coupled to a constituent having high
magnetostriction (Terfenol D and Metglas) (47). When selecting a piezoelectric material,
factors such as dielectric constant, piezoelectric loss, Curie temperature, piezoelectric strain
constant, and electromechanical coupling factor should be considered. In addition, the selection
of magnetostrictive materials considers the magnetic permeability, coercive magnetic field,
magnetostriction, Curie and Neel temperatures (47).
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1.5 Piezoelectric Biopolymers and Biodegradable Polymers
The biopolymers Cellulose and Collagen exhibit inherent piezoelectricity (Table1) due
to the uniqueness of their molecular structure. The asymmetric crystalline structure of cellulose
can generate piezoelectricity (49) whereas Deoxyribonucleic acid (DNA) generates its
piezoelectricity due to rotation of dipoles in the backbone (50). This type of shear
piezoelectricity is in contrast to that of the commonly used, Poly(vinylidene fluoride) (PVDF),
where the molecular structure itself does not exhibit inherent piezoelectricity and it is required
that the dipoles are oriented with an applied stress and/or electrical poling (51). For instance,
the β-crystalline phase of PVDF exhibits piezoelectricity, in which case the dipoles are aligned
parallel to the axis of the polymer chain (52).

Table 1: Piezoelectric constants of different bio polymers (53)
Bio-Polymers

Piezoelectric Constant (pC/N) d14

Cellulose (wood)

⁓ 0.1

Chitin (crab shell)

⁓ 0.2

DNA (salmon)

0.07

Collagen (bone)

0.2

Other than the natural biopolymers, biodegradable polymers like Polylactic acid (PLA), Poly3-hydroxybutyrate and Polypropylene oxide exhibit shear piezoelectricity (Figure1.7). These
biopolymers exhibit small piezoelectric constants that depend on the chirality of the carbon
atom (53) (Table 2). The biodegradable

Poly(3-hydroxybutyrate-co-3-hydroxyvalerate)

PHBV formed by polymerization of Poly-3-hydroxy butyrate with 3- hydroxy pentanoic acid
has been used for drug delivery applications, Pacheco et al. (54) and Lionzo et al. (55). Further,
Amaro et al. (56) synthesized CFO/PHBV ME composites having various morphologies,
spheres, fibers and scaffolds, show their potential usage in tissue engineering. Specific to this
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thesis, PLA is also a biodegradable piezoelectric polymer previously used to synthesize ME
composites (57) because of its biocompatible, nontoxic and biodegradable nature (58). PLA
displays piezoelectricity when in the L-lactic form and is due to polarization changes that occur
due to the C=O group rotation (59). Several PLA based ME particulate composites have been
reported. For example, Correia et al.(60) synthesized CFO/PLA ME composite microspheres
while Zhang et al. (58) reported Fe3O4/PLA ME composite nanofibers. In general, the use of
piezoelectric biopolymers in ME composites has been minimal to date though is expected to
rapidly increase to their several advantages, including inherent piezoelectricity, lowtemperature processing, high flexibility and conformability, high electric breakdown field,
nontoxicity and biodegradability (39).

Poly L- lactic acid

Poly-3-hydroxybutyric acid

Polypropylene Oxide

Figure 1.7-Molecular structures of biodegradable, piezoelectric polymers of Polylactic acid (PLA)- the
confirmation that generates piezoelectricity, Poly-3-hydroxy butyrate and Polypropylene oxide.

Table 2: Piezoelectric constants of different biodegradable polymers (53).
Bio-Polymers

Piezoelectric Constant (pC/N)

Poly-L-lactic acid

d 25

10

Poly-3-hydroxy butyrate

d 25

1.3

Polypropylene oxide

d 25

0.1
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1.6 Core/Shell ME Particulate Composites
The core/shell ME particulate composites represent a novel advancement in 0-3 connectivity
to enhance the coupling between two phases and ultimately increase the ME response (8).
Generally, these particulate composites contain a magnetic core embedded in a piezoelectric
shell, with either a single or multiple magnetic core (Figure 1.8). Chaudhuri et al. (61) found
CFO/BTO core/shell ME composites demonstrate a higher ME coefficient (8130 µV/cm Oe)
in comparison to standard mixture of CFO and BTO (101 µV/cm Oe). Similarly, Duong et al.
(62) found these types of core/shell particles exhibit 8 to 18 times higher ME coefficients. In
addition, reverse core/shell ME composites comprising a magnetic shell and piezoelectric core
(63), evidently exhibit a converse ME effect (64).
Mixing of two phases together is the most common approach for fabricating core/shell
structures, for example, using emulsification, sol-gel methods and electro-spraying (65, 66).
However, this does not always ensure homogenous dispersion of magnetic particles in the
piezoelectric matrix, as the magnetic particles tend to agglomerate. If the magnetic particles
are not well dispersed, their conductivity will result in ME voltage loss due to poor resistance
and current leakage (67). To improve dispersion and enhance the effective strain transfer from
the magnetic-to-electric phase, magnetic particles have been treated with a precursor solution
prior to mixing with the piezoelectric phase (62, 68, 69). For example, Fe3O4 particles were
treated with oleic acid or citric acid to enhance its stability (70).

Figure 1.8-ME particulate composites with different core/shell structures
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So far distinct types of ceramic (47, 62, 67-69, 71-73), CFO/BTO, Fe3O4/PTO, CFO/PTO,
CFO/PZT and polymer-based (58, 60, 74-76), CFO/PLA, CFO/PVDF, Fe3O4/PLA ME
composites have been reported. The majority of research in ME composites has in fact
investigated the ceramic core/shell composites. Corral-Flores et al. (77) developed CFO/BTO
ME composites with maximum ME coefficient of 1.48 mV/cm Oe. Also, Curecheriu et al. (78)
using Ni0.5Zn

0.5Fe2O4/

BTO composites found that these composites have higher dielectric

properties.

1.6.1 Polymer-based ME Core/Shell Microspheres
According to the materials used in the synthesis of ME core/shell particles, the latter can be
classified as inorganic/inorganic (79) and inorganic/organic. Piezoelectric polymer-based ME
composites are the most common inorganic/organic ME core/shell composites. Generally, the
polymer shell is formed through electrostatic interactions, osmotic depletion, or hydrogen
bonding forces onto magnetic core nanoparticles. There are various available techniques for
the core/shell microsphere synthesis, such as nanoprecipitation (80), ring-opening
polymerization (76), polymer grafting (81) and sol-gel condensation. Grafting of polymers on
surface-functionalized magnetic cores demonstrated a higher stability compared to the other
techniques as it is covalently bonded, for example PLA grafted on Fe3O4, (36). In this thesis,
we used emulsion techniques for synthesis of core/shell ME polymer composites as it is simple,
fast and requires less quantity of chemicals (8, 57, 74, 82). Furthermore, there have been only
a few studies on the ME effect of the polymer-based ME microspheres. Using electrospray
processing, Goncalves et al. (83) developed CFO/PVDF microspheres that exhibited an ME
response of 5pC N-1, which avoided some drawbacks of traditional polymer based ME
composites such as agglomeration and the difficulty in miniaturized form (61).
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Of course, there have been numerous studies that have presumably “inadvertently”
developed ME composite microspheres, i.e. without the specific intention of utilizing the
classical ME mechanisms described in section 1.1, for a wide-range of application. Ribeiro et
al.(84) fabricated PVDF ME particles to explore their potential for energy generation and
storage applications while Maceiras et al. (85) has discussed the use of Polyamide-CFO
particles as sensors under high temperatures. They have also featured prominently in
biomedical applications, including for drug delivery systems. Chorny et al. (86) used PLA
spheres for the Paclitaxel drug delivery. Zhou et al. (87) studied the use of PLGA and PLAFe3O4 ME microspheres for cancer treatment by inserting Interferon into the spheres, whereas
Zavisova et al. (88) used indomethacin, an anti-inflammatory drug, incorporated into PLAFe3O4 spheres. Similarly, Fengxia et al. (89) studied the same ME system by incorporating
Curcumin, which is used in cosmetics.
While there have been extensive studies on the synthesis of core/shell particles, the
determination of their ME response is relatively unknown and problematic due to several
reasons. Namely, an ME response can typically only be measured if the particles are compacted
together to form a bulk film. Henceforth, it is difficult to pinpoint ME measurements on single
particles. Experimentally, this is a challenging task and the ME voltage responses may be
expected to also vary from particle to particle due to their non-uniform size distribution. Lastly,
the alignment of dipoles and piezoelectric geometry consideration in spherical morphology
structures makes prediction of the piezoelectric response less-well understood. To address
some of these challenges, the use of Piezoresponse Force Microscopy to measure the ME effect
on ME nanostructures such as individual particles and nanofibers has been used (90) .
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1.7 Biomedical Applications of Core/Shell ME particles
In recent years, the use of ME particles, specifically via the ME effect, has been demonstrated
for drug delivery and regulation of ion channels using magnetic-to-electrical stimulation (91).
The core/shell ME nanoparticles are generally attractive (92) due to their smaller size, enabling
interactions with cellular components (82, 93, 94). Secondly, the ability of the particles to
respond to magnetic stimuli enables them to be magnetically directed or transported to a
specific site, magnetically controlled for the release of drugs, or magnetoelectric effect for
stimulation (8, 95). Early research based on pure magnetic nanoparticles with biocompatibility,
such as Fe3O4 and γ-Fe2O3 (96), used for ME composites to avoid the agglomeration formed
by pure particles. Having a piezoelectric polymer coating on the magnetic particle surface was
also beneficial for allowing higher dispersibility (97) and permitting longer circulation without
recognition by the immune system.
Studies done by Amaro et al. (56) on synthesized CFO/PHBV ME composites
demonstrated that these ME systems are also appropriate for biological applications due to their
non-toxic nature. This is further supported by Rao et al. (67) using CFO/BTO. Besides, Zhao
et al. (98) reported that the PLA-based ME composite particles are hemo-compatible.

1.7.1 Drug Delivery and Release

1.7.1.1 Targeted drug delivery using ME carriers
Targeted drug delivery is a highly promising approach in chemotherapy, particularly for
selected targeting of tumour cells from normal cells (44, 82, 92, 96, 97). In general, the main
objective of magnetic carriers is to avoid side effects and reduce the required drug
concentration for treatment. In targeted drug delivery for chemotherapy, ME nanoparticles
have been injected into the circulatory system and directed to the tumour site via application
16

of a magnetic field (91). The field strength and size of the particle governs the effectiveness of
the therapy by targeting the exact affected cells (82, 93, 94).
ME particles have been developed for specific drug delivery, especially in
chemotherapy, but have only been recently reported. Chorny et al. (86) investigated paclitaxel
loaded PLA ME particles for treatment of a tumour using A10 artery cells. ME nanoparticles
developed by Nair et al. (99) were applied to anti-HIV drug delivery, where azidothymidine
50-triphosphate was loaded into CoFe2O4/ BaTiO3 ME nanoparticles.

Figure 1.9-Schematic representation of the process of drug delivery and release from ME particles
with an applied magnetic field (91).
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1.7.1.2 ME Mechanisms for Drug Release
The mechanism by which the applied magnetic field can induce the drug release may differ
depending on the design of the ME nanoparticle and applied DC and AC fields. For example,
in the case where both the ME particle and cell membrane have negative charges, the
electrostatic repulsion force can facilitate the transport of drug loaded ME nanoparticles
through a capillary to the tumour site (91, 100). At the site, a field-controlled nanoelectroporation technique firstly can be used to transfer the drug into the cell (Figure 1.9). The
electric field generated on the drug loaded ME nanoparticles, through an external magnetic
field via a ME effect changes the polarity of ion channels present on cell membranes of tumour
cells (8). This enables opening up of pores of the membrane for the penetration of ME
nanoparticles (100).
Drug release can also be initiated via the application of an AC magnetic field to break
bonds on the ME particle surface (67). When the applied DC field (H) is higher than the
threshold (Hth) for nano-electroporation in tumour cells, an AC external magnetic field then
facilitates the drug release within the tumour cell. This was implemented using an anti-HIV
drug, azidothymidine 50-triphosphate (AZTTP) bound to ME nanoparticles via electrostatic
interactions (Figure 1.10). The induced electric dipole moment within the ME nanoparticles
upon application of non-zero magnetic field modulated the dipole moment results in the
breaking of original symmetry of charge and thus breaking the bonds between AZTTP and ME
nanoparticles to release the drug (Figure 1.10) (101).
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Figure 1.10-Illustration of drug release from ME particles, a) the charges distribution at ‘0’ field. b) A
new dipole formation with an applied AC field. c) With the field higher than the threshold, bond
breakage happens d-e) applied the same field to opposite direction to break the bonds in other sides
(101).

In order to accomplish drug delivery, ME nanocomposite’s electroporation to enter the
intercellular environment is crucial. Betal et al. (102) studied the nano-electroporation
mechanism using CFO/BTO ME composites that enhances internal up take of ME
nanocomposites via opening of pores on the cell membrane.
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1.7.2 Cell Identification and Stimulation

1.7.2.1. As a NMR Sensitive Probe
ME nanoparticles have been applied to identify different types of tumour cells (103) by
detecting changes in the electric field configuration of cell membranes (103-105). Nagesetti et.
al (106) found that core/shell CFO/BTO ME particles distinguish the electric field of cancer
cells. This is achieved by the CFO/BTO composites converting the electric signal into a
magnetic field pattern via the converse ME effect. This magnetic field pattern can then be
measured by Nuclear Magnetic Resonance Spectroscopy (NMR) system. As illustrated in
Figure 1.11, three different cancer cells of U87-MG, SKOV-3 and MCF-7 exhibit different
NMR patterns with ME composites. Thus, these ME composites function as a sensor for
identifying different cancer cells and their progression stage. Moreover, it was found that the
NMR output signal for cancer cells are different from normal cells.

Figure 1.11-Continuous Wave-NMR spectra for 3 different cancer cell types, glioblastoma cells U87MG, ovarian carcinoma cells SKOV-3, breast adenocarcinoma cells MCF-7, in the presence of ME
nanoparticles (106) .
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1.7.2.2 Nerve Cell Stimulation
Guduru et al. (95) studied CFO/BTO ME composite system for brain nerve cell stimulation by
incorporating ME composite nanoparticles into mice. With an applied magnetic field gradient
of 3000 Oe/cm, the injected ME composites could enter the brain through the blood brain
barrier and localize to specific parts of the brain by changing the magnitude of the applied DC
field. AC magnetic field of 100 Oe in the frequency range of 0-20 Hz is applied to the ME
composites which then stimulated the brain neural tissue via an electric field generated on
composites using ME effect. The effect of the stimulation on the brain signals was recorded
using electroencephalography channels (EEG) (Figure1.12).

Figure 1.12-Illustration of the brain nerve stimulation process using CFO/BTO composite system; AB) Transportation of the ME composites in to specific parts of the brain using DC magnetic field and
C) brain nerve stimulation using AC magnetic field (95).
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1.8 Thesis Outlook
Magnetically directed drug delivery to the target cells and controlled release remotely via the
ME mechanism has gained recent research attention to develop injectable magnetoelectric
core/shell composites for biological applications (100, 107).
To date most of the ME particles have relied upon ME ceramics. CFO/BTO ceramic
ME composites are mostly studied for drug release applications, Rodzinski et al. (100) and
Nair et al. (99) and cell stimulation applications, Guduru et al. (95). A few studies have
demonstrated polymer-based ME particles (86) (58),

however their magnetoelectric

application in biomedicine is not recorded so far.
Utilising piezoelectric polymers with biodegradable and biocompatible properties
would be beneficial for magnetoelectric composites in biomedical applications. For example,
Poly Lactic acid is extensively used for drug release, Li et al.(89) and Bouza et al. (75). Other
biocompatible

polymers

like

cellulose

(108)

and

Poly(3-hydroxybutyrate-co-3-

hydroxyvalerate) PHBV (56) have also been used to develop ME composites. Further, the
studies done by Correia et al. (60) and Amaro et al. (56) demonstrate that these ME composites
are non-toxic.
Therefore, a key focus of the thesis was to explore PLA within ME composites as a
drug release system. An important consideration was to fabricate microspheres due to their
advantages in biomedical applications. More specifically, the project aimed to develop and
apply the mechanism of magnetic-to-electrical conversion using PLA-based ME composite
microspheres as remotely addressable and contactless polarizable systems, which could be
applied in drug delivery. The biodegradable and biocompatible nature of PLA would be
beneficial and the administration of these microspheres relatively practical. This thesis
describes the synthesis of drug incorporated ME core/shell spheres and investigates their
application as a controlled drug release system driven via an external magnetic field.
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Therefore, the aims of thesis are to:

Aim 1: Synthesize magnetoelectric (ME) microspheres based on core/shell magnetic/PLA
nanoparticles using emulsion methods. The effects of the polymer and magnetic
nanoparticle concentration on the emulsion synthesis are also investigated.

Aim 2: Characterize the piezoelectric and magnetic properties of the ME microspheres.

Aim 3: Investigate the application of the ME microspheres on drug release of the antiinflammatory drug, Dexamethasone, under the control of an externally applied
magnetic field.
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2.

2.1

Materials and Methodology

Materials

Materials
Polymers

Company
Poly(DL-lactide) 2.0dl/g

Corbion Purac, Netherlands

PolyVinyl Alcohol; Mw: 89000-

Sigma-Aldrich, Australia

98000
Nanoparticles

Fe3O4

Nanostructured& Amorphous
Materials Inc., USA

Drug

CFO/ CoFe2O4

Sigma-Aldrich, Australia

Dexamethasone, micronized,

Spectrum Chemical

USP

Solvents

Company

Dichloromethane

Fisher Scientific, UK

Methanol

Chem-Supply

Ethanol

Chem-Supply

PBS pH 7.4

Sigma Aldrich

Acetonitrile

Sigma Aldrich

2.2

Synthesis of PLA-Based ME Composite Microspheres

Preparation of PLA microspheres comprising magnetic nanoparticles can be achieved via
different methods, including nanoprecipitation, emulsification, polymerization and sol-gel
condensation (109). The emulsification method was chosen due to its simplicity, less chemical
consumption. Both single and double emulsification methods were investigated. In the single
emulsion method, both the polymer and magnetic particles are in the organic phase, which is
then emulsified with the PVA surfactant in aqueous medium (58, 60). In the double emulsion
method, the emulsification is performed twice. Firstly, the polymer in the organic phase is
emulsified with magnetic particles in aqueous phase to form emulsion 1. Thereafter, the
mixture is emulsified again with the PVA surfactant in aqueous medium to form emulsion 2
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(74). Due to the failure of forming microspheres under conditions described below for the
double emulsification, all samples in this thesis were prepared from single emulsions. PVA
was used as the surfactant to increase the stabilization and dispersion of formed microspheres
(110).

2.2.1 Double Emulsion Method
As explained above in section 2.2, the synthesis via double emulsion method involves having
polymer and magnetic particles in two different phases, which are immiscible. For the
following synthesis, water and dichloromethane was selected as the two phases.

2.2.1.1 Synthesis of Fe3O4/PLA Core/Shell Microspheres
Following previous methods by Gomez-Lopera et. al (74), the procedure was based on the
water-oil-water (W/O/W) emulsion (See Figure 2.1). 0.6 g of Poly(DL-lactide) was dissolved
in 40 ml of Dichloromethane. A 20 ml aqueous solution of 20% Fe3O4 magnetic nanoparticles
was then added to the PLA in Dichloromethane and the mixture was homogenized at 2700 rpm
for 2 minutes to obtain the first emulsion (W/O). The mixture was added into 250 ml of 1%
Polyvinyl Alcohol solution, which was homogenized at 2700 rpm for 2 minutes to obtain the
second (W/O/W) emulsion. The second (W/O/W) emulsion was sonicated at R.T. for 3 hrs to
evaporate the organic solvent. The resulting microspheres were washed with deionized water
and centrifuged at 5000 rpm for 10 minutes. Microspheres collected by centrifuge were washed
again with deionized water several times and freeze dried for 24 hrs until further use. The same
procedure was repeated to synthesize PLA microspheres without adding magnetic particles.
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Figure 2.1- Schematic process for the fabrication Fe3O4/PLA core/shell microspheres via double
emulsion method

It is noted that the double emulsion method was not used to synthesize CFO/PLA
spheres, as all the previous work based on CFO/PLA composites are used single emulsion
method as explained below (60).

2.2.2 Single Emulsion Method
2.2.2.1 Synthesis of Fe3O4/PLA and CoFe2O4/PLA Core/Shell Microspheres
Figure 2.2 illustrates the single emulsification process which was used to synthesize
microspheres. A similar procedure was used based on the oil-in-water (O/W) according to
previous work in (58). 0.5g of Poly (DL-lactide) was dissolved in10 ml of Dichloromethane
and 40 mg of Fe3O4 or CoFe2O4 magnetic nanoparticles was added to the PLA in
Dichloromethane. The mixture was then added to 20 ml of a 1% Polyvinyl Alcohol solution,
which was homogenized at 1000 rpm for 2 minutes and sonicated at R.T. for 1 hour to
evaporate DCM. The microsphere suspension was washed with deionized water and collected
by centrifuging at 5000 rpm for 10 minutes. The microspheres were washed again with
deionized water several times and freeze dried for 24 hrs. The same procedure was repeated to
synthesize PLA microspheres without adding magnetic particles.
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Figure 2.2- Schematic process of the fabrication of CFO/Fe3O4 -PLA core/shell microspheres via single
emulsion

To determine the effect of PLA concentration on particle size, microspheres were prepared
according to the same procedure by maintaining the magnetic nanoparticle concentration
constant at 0.4 w/v %, with five different PLA concentrations (w/v %) of 1, 2.5,5, 7.5 and 10.
Similarly, to determine the CFO concentration effect on particle size, microspheres were
prepared using the above procedure with changing CFO concentrations from 0.2 to 1.2%
(w/v%) at 5% PLA concentration. Likewise, CFO concentration changes from 0.2-1.2% at
2.5% PLA concentration.

2.2.2.2 Dexamethasone Loaded ME Core/Shell Microspheres
Due to the success of the single emulsion method using CFO nanoparticles, a modified method
of Hickey et. al.(111) was used to synthesis core/shell CFO/PLA microspheres loaded with the
anti-inflammatory drug, Dexamethasone (DEX). 20 mg of Dexamethasone was dissolved in
10 ml of 9:1 Dichloromethane: Methanol mixture containing 0.5g of Poly(DL-lactide). 40 mg
of CFO magnetic nanoparticles was then added to the same mixture. Thereafter, the mixture
was added into 20 ml of a 1% Polyvinyl Alcohol solution, which was homogenized at 1000
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rpm for 4 minutes and sonicated at R.T. for 5-6 hours to evaporate the organic solvent. Longer
sonication times were used compared to the above synthesis 2.2.2.2 because the solvent
mixture of Methanol and Dichloromethane required longer time for evaporation than pure
Dichloromethane. The microspheres were washed with 1ml of Acetonitrile to remove the traces
of excess Dexamethasone and centrifuged at 5000 rpm for 10 minutes. The residual
microspheres were washed with deionized water several times and freeze-dried overnight. The
same procedure was repeated to synthesize Dexamethasone loaded PLA microspheres without
adding CFO magnetic particles.

2.3 Characterization of Microspheres

2.3.1 SEM/TEM Imaging
The morphology of the microspheres was imaged using a JEOL-JSM 7500 Scanning Electron
Microscope (SEM) with accelerating voltage of 5 kV and JEOL-JEM 2010 Transmission
Electron Microscope (TEM) with accelerating voltage of 200 kV. For SEM imaging, a small
amount of microspheres were deposited onto carbon tape, which attached to the stub and coated
with a thin 15 nm Pt layer using sputter coating. For TEM imaging, the samples were prepared
by dispersing the microspheres in a 50:50 water: ethanol mixture and directly depositing onto
a TEM grid. The particle size was quantified from SEM images using Image J software.
Correlation and regression analysis were performed to determine the effect of PLA and CFO
concentration on particle size.

2.3.2 Dynamic Light Scattering technique (DLS) Analysis
For the DLS analysis (Zeta Sizer (Malvern Instruments)), 1 mg of CFO/PLA microspheres was
dissolved in 100 ml of distilled water and sonicated for about 5 minutes before testing.
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2.3.3 FTIR Analysis
The FTIR spectroscopic analysis was performed using a Shimadzu FTIR prestige-21
spectrometer to determine the presence of PLA and either Fe3O4 or CFO in the microspheres.
The samples were mixed with KBr powder and pressed into a disc to obtain a wide spectral
range of 500-4500 nm, as otherwise the peaks related to Fe–O bond vibrations cannot be
detected. Moreover, KBr has no significant absorption lines in this transmittance region and
does not interfere with the spectrum. The samples of pure solids of PLA, pure CFO and
CFO/PLA microspheres were directly analysed.

2.3.4 Magnetic Properties
The magnetic properties of the pure CFO nanoparticles and CFO/PLA microspheres were
measured using the 14T Physical Property Measurement System (PPMS) in the field range of
-20,000 to 20,000 Oe at room temperature (data points were obtained at each 500 Oe). The
obtained data was analysed using the Origin 9.0 software.

2.3.5 Piezoresponse Force Microscopy (PFM)
Piezoresponse Force Microscopy was used to understand the piezoelectric properties of the
CFO/PLA microspheres. Samples were prepared by redissolving microspheres in water,
sonication for a few minutes at room temperature, and then drop cast on a 50mm Pt coated
glass slide. A conductive tip (EFM-50, Nanosensors) with Pt/Ir coating and spring constant of
2.8 N/m was used. PFM height, amplitude and phase images were obtained using Dual AC
Response Tracking (DART). The contact resonance frequency varied in the range of 285-295
kHz for different samples. Switching Spectroscopy-PFM (SS-PFM) was used to obtain the
hysteresis loops. The applied voltage during the SS-PFM measurement was in the range of ±
29 V, with a frequency of 0.5 Hz. An external amplifier was used to increase the applied voltage
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to enable a fully saturated switching dynamic. A driving amplitude was set to be 1.2 V for all
measurements. During the process, 5 cycles of sweeping triangles/square waves were used to
obtain a single curve which make sure the reproducible results. Igor Pro 6.36 Software was
used to obtain the hysteresis loops and the data analysis done by using Origin 9.0 Software.

2.4 Dexamethasone Release from Microspheres with Applied Magnetic
Fields
1.5 mg of Dexamethasone loaded microspheres (CFO/PLA and PLA) were dissolved in 15 ml
of PBS in a centrifuge tube. The tube was placed in a Helmholtz coil and an A.C. magnetic
field (10 Oe, f=3Hz, Vac=50 mV) was applied continuously for a total of 2 hours. A 0.5 ml
aliquot of the PBS was removed every 10 minutes, giving a total of 12 samples for
measurement of the Dex release. The effect of magnetic field strength on drug release was
investigated by applying 5 Oe, 10 Oe and 20 Oe at a constant frequency of 3 Hz for 1-hour
duration. Dex loaded PLA microspheres with and without magnetic nanoparticles were also
tested, in addition to control samples that were measured without applying magnetic field. All
samples were maintained at pH=7.4 and temp=37° C, by keeping the sample in a water bath
until the temperature was reached. This is usually done every ten minutes just after the 0.5 ml
aliquot was taken during the magnetic stimulation.
However, it is hard to maintain the constant temperature throughout the experiment, it
varies about 4-5°C degrees because of the fixed distance between the Helmholtz coils in the
experimental set up was not enough to contain a constant temperature water bath as shown in
Figure 2.3.
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Figure 2.3- Experimental set up for the drug release study with the applied magnetic field H a.c.

2.4.1 Dexamethasone Release Analysis using HPLC
Dex concentration in aliquots was measured using an Agilent HPLC 1260 Quaternary system
with a ZORBAX ECLIPSE PLUS C18 column. HPLC analysis was carried out at 40ºC with a
flow rate of 1 ml/min and mobile phase of 35:65 Acetonitrile: water. The acetonitrile/water
ratio is an important factor; less acetonitrile gives an increase in the elusion time of drug.
Dexamethasone peak can be seen after 4 minutes of sample injection (10 µl). In the HPLC
analysis, the dexamethasone was eluted at ~ 4 minutes whereas PBS was eluted at earlier at ~
1 minute of which the latter gave a broad peak. This was important as the PBS related peaks
should not overlap with the compound peak for quantitative analysis. The measurements were
done at a wavelength of 242 nm, which gives a maximum peak intensity.
In order to perform apparatus calibration (Fig. 2.4), a standard sample series was
prepared using a stock solution of 1mg/ml of dexamethasone/ethanol. 0.1 ml of the solution
was removed and added to an Eppendorf tube with 1.9 ml of PBS and vortexed to mix well.
Then, 0.8 ml of solution was removed and added to another tube and topped up with 0.8 ml of
PBS. This was repeated until 10 standards were created (See Table 3).
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Figure 2. 4-Calibration curve for Dexamethasone standards

Table 3: Standard Dexamethasone sample preparation
Sample label
S1
S2
S3
S4
S5
S6
S7
S8
S9
S10

Concentration (ng/ml)

Previous solution (ml)

50000
25000
12500
6250
3125
1562.5
781.3
390.6
195.3
97.7

0.1
0.8
0.8
0.8
0.8
0.8
0.8
0.8
0.8
0.8

Filtered PBS (ml)
1.9
0.8
0.8
0.8
0.8
0.8
0.8
0.8
0.8
0.8

All the samples and standards were filtered into vials using a 0.4 µm syringe filter. The total
drug release at each time was calculated by adding samples to the previous samples. For
example, the total cumulative drug released at 30 minutes (T30) = mass of drug released at 30
minutes (S30) + S20+ S10+ S0 and the average cumulative dexamethasone concentration (ng/ml)
versus the time (min) was plotted. Each measurement was repeated 9 times and carried out
under the same experimental conditions.
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3. Experimental Results

3.1 Characterization

3.1.1 Morphology of Microspheres
Commercially available Fe3O4 nanoparticles (Nanostructured& Amorphous Materials Inc.,
USA) with an average size of 30 nm were used in the synthesis (Fig. 3.1a). However, both the
double and single emulsification synthesis using Fe3O4 nanoparticles failed to form Fe3O4
nanoparticles/PLA core/shell microspheres (Fig. 3.1b-c). Figure 3.1 b depicts the polymer
interacting with the Fe3O4 magnetic particles but no spheres were observed. By analysing TEM
images these observations of the polymer interaction with the magnetic nanoparticles were seen
rarely in these samples. Failure to synthesize the microspheres is most probably due to the
lower solubility of Fe3O4 nanoparticles in both aqueous and dichloromethane medium. In order
to achieve a successful emulsion, the magnetic nanoparticles need to be well dispersed in the
PLA. The Fe3O4 nanoparticles are commercially supplied with 1% Polyvinylpyrrolidone (PVP)
as a stabilizer, which clearly makes Fe3O4 nanoparticles insoluble in hydrophobic PLA. This is
further supported by the successful formation of PLA microspheres in the absence of Fe3O4
(Fig. 3.1d).
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Figure 3.1-TEM images of a) pure Fe3O4, b) Fe3O4/PLA obtained by single emulsion, c) Fe3O4/PLA
obtained double emulsion d) PLA-PVA composite particles

Unlike the Fe3O4 nanoparticles, the commercially available CFO nanoparticles, having 30 nm
average particle size, were well dispersed in hydrophobic dichloromethane. The single
emulsion synthesis of CFO nanoparticle/PLA core/shell microspheres was successful in
producing CFO nanoparticles encapsulated in PLA microspheres (Fig. 3.2). SEM images show
the microspheres were spherical in shape with smooth surfaces (Fig. 3.2a-b). As shown in
Figure 3.2a, smaller microspheres were attached to larger CFO/PLA microspheres and Figure
3.2b shows that some of the pure PLA particles had collapsed.
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Figure 3.2-SEM images of a) CFO/PLA microspheres b) pure PLA microspheres

TEM images in Figure 3.3 illustrate three different microspheres exhibiting an ‘imperfect’
perfect core/shell structure, where the CFO nanoparticles (dark areas) were not homogeneously
dispersed and tended to agglomerate within the PLA microsphere. In particular, uncoated
magnetic particles could not be observed on the surface, which implies that all magnetic
particles encapsulated in the polymeric matrix.

PLA
A
CFO

Figure 3.3-TEM images of several CFO (dark areas)/PLA microspheres illustrates core/shell structure.
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For the synthesis, dichloromethane was chosen as the solvent for two reasons, including
increasing the solubility of PLA and lowering the boiling point (35 ºC) for facilitating
evaporation of excess DCM at room temperature. This minimized any effect on the
microsphere synthesis due to further heating, for example, the removal of residual chloroform
requiring heating (B.P of chloroform is 61 ºC). In addition, qualitative observations showed
that the homogenization speed was a critical factor, as speeds of > 1200 rpm lead to irregular
morphologies or break-up of the microspheres, while lower speeds did not support the
formation of microspheres (60). For this reason, 1000 rpm was selected as an optimum speed
for the synthesis.
The diameter of the microspheres was determined by Image J software analysis of SEM
images (n = 60 spheres). The average diameter of a CFO/PLA microsphere was 3.8 ± 1.6 µm,
while the DLS technique measured an average size of 2.80 ± 0.07 µm. The difference between
values from SEM and DLS is believed to be due to latter approach were done in an aqueous
environment where particles are not homogeneously dispersed, larger particles can be
aggregated and deposited in the cuvette. Thus, these particle sizes may not be included in the
final results. The SEM analysis enabled only selected individual microspheres to be considered.
In contrast, the average size of pure PLA microspheres without magnetic nanoparticles is 8.46
± 1.5 µm, which is almost twice in size compared to the ME composite microspheres. Upon
successful synthesis of 0.4% CFO/5% PLA microspheres, further characterization was done
with spheres prepared under these conditions.
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3.1.2 FTIR Analysis of ME Microspheres
a)
b)

c)

1300-1000

Figure 3.4-FTIR spectra of a) CFO/PLA b) pure CFO and c) pure PLA

Figure 3.4 shows FTIR spectra of pure CFO nanoparticles, pure PLA and their CFO/PLA ME
composites. The peak near 590 cm-1 in spectra of pure CFO and CFO/PLA indicates vibrations
of the Fe–O bond in CFO. Peaks around the 860-960 cm-1 region in both pure PLA and
CFO/PLA microspheres represent the polymer backbone stretching, while the bands at 925,
955 and 1454 cm-1 represents the C–C carbon backbone stretching. The peak at 1751 cm-1 in
both PLA and CFO/PLA spectra represents stretching vibrations of ester carbonyl, C=O groups
of the PLA. The weak bands at 1080 and 1451 cm-1 were ascribed to asymmetric vibrations of
C–H bonds in –CH3. Peaks in the region of 1300-1000 cm-1 represent C–O–C asymmetric
vibrations. Peaks at 1433 and 1377 cm-1 indicate the asymmetric and symmetric vibrations of
–CH3 groups. Finally, the absence of 920 and 1510 cm-1 peaks in CFO/PLA spectrum indicates
that the microspheres are in an amorphous state (60). Thus, we can conclude both the PLA and
CFO present in the CFO/PLA microspheres.
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3.1.3 Magnetic Properties of Microspheres
The magnetic properties of the CFO/PLA ME microspheres were confirmed by applying an
external magnetic field to the microspheres in aqueous medium. As illustrated in Figure 3.5a,
the ME composite microspheres were attracted towards the external magnet and completely
separated out from the solution. Good separation and lack of microspheres remaining in the
solution also confirmed that CFO nanoparticles were predominately associated with the PLA
polymer microspheres. Physical Property Measurement System (PPMS) characterization in the
field range of -20,000 to 20,000 Oe at room temperature (data points were obtained at each 500
Oe) gave maximum magnetization (MS) values of 56.15 emu/g and 5.17 emu/g for pure
CoFe2O4 and CoFe2O4/ 5% PLA microspheres, respectively (Fig. 3.5b). It is noted that the
process used to fabricate the CFO/PLA microspheres has a quite poor efficiency to obtain the
maximum magnetization value.

Figure 3.5-Magnetic behaviour of the CFO/PLA ME composite microspheres b) Magnetization versus
applied magnetic field for pure CFO and CFO/PLA

The wt% content of magnetic CFO within the microspheres can be estimated using the
maximum magnetization values from hysteresis curves in Figure 3.5b and using equation 4.
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CoFe2O4 wt% in microspheres =

Maximum magnetization of microspheres
𝑀𝑎𝑥𝑖𝑚𝑢𝑚 𝑚𝑎𝑔𝑛𝑒𝑡𝑖𝑧𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑝𝑢𝑟𝑒 CoFe2O4

× 100

(eq: 4)

Accordingly, only 9% of CFO magnetic nanoparticles were encapsulated in the microspheres,
presumably due to the CFO nanoparticles not being homogenously dispersed through the
solution and thus not encapsulated in the PLA during emulsification. Excess CFO nanoparticles
would then be removed during the washing step. Further PPMS done with 2.5%, 5% and 10%
PLA microspheres with the same CFO content show that their MS values of 8.57521, 5.17034
and 4.5684 emu/g decreased with the respective increase in polymer concentration.

Figure 3.6-Magnetization versus applied magnetic field for 2.5% PLA-0.4% CFO, 5% PLA- 0.4% CFO
and 10% PLA- 0.4% CFO
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PLA

CFO

Spheres maximum

Calculated CFO

Calculated CFO

Concentrati

CFO+PLA

weight

magnetization

weight in

wt % in

on (W/V %)

weight(g)

(g)

(emu/g)

microspheres(g)

microspheres

2.5

5.896×10-1

4×10-2

8.57521

1.53×10-3

15.27

5

6.634×10-1

4×10-2

5.17034

9.20 ×10-4

9.21

10

8.086×10-1

4×10-2

4.56841

8.13×10-4

8.13

Table 4: Size, magnetization, CFO weight and CFO wt/wt% in PLA microspheres

Table 4 summarizes the effect of the PLA concentration on the CFO encapsulation efficiency,
confirming a decrease in CFO encapsulation efficiency with increasing PLA concentration.
One possible reason for this finding is the non-homogenous dispersion of CFO magnetic
particles during the emulsification process.

3.1.4 Piezoelectric Properties of the Spheres
To understand the piezoelectric effect, it is important to study the dynamics of dielectric
polarization. Switching Spectroscopy Piezoresponse Force Microscopy (SS-PFM) is a
technique that provides information on the polarization switching through the nanoscale
displacement of a piezoelectric material (112, 113). Figure 3.7A illustrates the operating
principle of Piezoresponse Force Microscopy (PFM). During the PFM measurement, when an
electric voltage is applied to the conductive tip, Vtip, that is in contact with sample surface,
eq 5: Vtip= VDC+VAC Cos ωt
(VDC is the applied DC voltage, VAC is the driving voltage and ω is the frequency of applied
bias) the sample displacement occurring due to the piezoelectric effect can be expressed as,
eq 6: A=A0+ Aώ Cos (ωt + ϕ)
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(A0-equilibrium state, Aώ -Amplitude of the first harmonic of response, ω-the frequency of
applied bias and ϕ- phase of the electromechanical response)
The output hysteresis loops of amplitude and phase represent the magnitude of the
electromechanical coupling (i.e. displacement of the sample) and the polarization direction,
respectively. For example, the application of an electric field parallel to the polarization
direction and along that direction causes the sample to expand and contract with the opposite
polarization (90).
In SS-PFM, the tip remains in contact with the sample in one X-Y position and the
hysteresis loops are obtained for both amplitude and phase. The on and off modes of the DC
voltage enable a more precise measurement of the sample piezoelectricity. During the off mode,
the response is only based on the piezoelectricity, where electrostatic interactions are not
involved. In the on mode, it is possible that both the electrostatic interactions and piezoelectric
effect contribute to the sample displacement (114).

A

B

C

Figure 3.7-A) Piezoelectric property measurement via PFM (113), B) PFM phase hysteresis loop and
C) PFM amplitude hysteresis loop (115).
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As an example, Figure 3.7 B-C illustrates the hysteresis loops of phase and amplitude
previously obtained for YMO films using SS-PFM. These images show the polarization
switching behaviour with the applied DC voltage (115).
For the PFM measurements in this work, the redispersed microspheres were drop cast
onto a Pt coated glass slide. Using the optical camera, the tip was placed in location where the
spheres were homogenously distributed on the substrate, i.e. not visibly aggregates, so as to
assist in undertaking measurements on individual spheres. A 15× 15 µm2 area of the sample
was scanned in the PFM mode (Fig. 3.8) to locate a single sphere and then repeated scanning
was performed in a smaller area (usually 3×3 or 5×5 µm2) to enable accurate positioning of the
tip on top of individual spheres for the SS-PFM phase and amplitude measurements.

Figure 3.8-PFM height images of CFO/PLA microspheres

The piezoelectric response can vary from sphere to sphere due to their size distribution.
For example, Zheng et al. (116) described the piezoelectric response value varies from 240.5
± 94.7 pm for Fe3O4 /PVDF nanofibers with the size range from 142 ± 29 nm. To overcome
above issues, we planned to also get an average response from several spheres.
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Figure 3.9-Piezoelectric property measurement via PFM a) PFM image of CFO/PLA microsphere bc), obtained PFM amplitude and phase responses at points 2, 3, 4 and 5 in the sphere.

Figure 3.9a shows a height image of a single core/shell microsphere. In this case, the
SS-PFM amplitude and phase responses were measured from four different positions on the
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sphere and the results for each position given in Figure 3.9 b. As observed in Figure 3.9 b-c,
there was unexpectedly no amplitude and phase response with the applied voltage. To confirm
the reproducibility of these results, measurements were carried out on a total of 10
microspheres. The same observation, i.e. no piezoelectric response, was observed in any of the
SS-PFM curves (data not shown).
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3.2 Effect of Emulsification Parameters on Microsphere Size
3.2.1 Effect of Polymer Concentration
There are several factors that affect the microsphere size during the emulsification process,
including the polymer and nanoparticle concentration. Theoretically, increasing the
mass/concentration of the chemical reactant increases the size of the sphere (117). Figure 3.10A
qualitatively shows that the size of CFO/PLA microspheres increases with increasing PLA
concentration. At the highest concentration of 10%, most of the spheres have lost their
morphology. Statistical analysis of using SEM image analysis and DLS confirmed the
increasing microsphere size with PLA concentration, with values ranging from ~ 2-10 µm using
a PLA concentration range from 1-10 W/V % (Fig. 3.10 B).

A

14

Mean diameter (µm)

B

12
10
8
SEM

6

DLS

4
2
0
1

2.5

5

7.5

PLA Concentration(W/V%)

10

Figure 3.10-A) SEM images of CoFe2O4/PLA microspheres in different PLA concentrations1-10%
(W/V%) and B) A plot of Mean diameter of particles measured by using DLS technique and analysis
of the SEM image using Image J VS PLA concentration (W/V%), error bars represent standard
deviation.
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Statistical T-test show that there was no significant difference between the calculated mean
diameter values using SEM and DLS (t=0.49; df = 8; p>0.05) (Fig. 3.10). ANOVA shows that
there was a significant difference among microsphere size at different PLA concentrations
(p<0.05), with the exception of between 1-2.5% and 5-7.5% (Fig. 3.11).

Figure 3.11-Statistical ANOVA analysis for SEM measurements, ***/** significant difference p<0.05,
NS-not significant difference p>0.05. Error bars represent standard deviation.
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3.2.2 Effect of CFO Concentration
The effect of the CFO concentration on microsphere size using a constant PLA concentration
of either 2.5 or 5% was analysed using SEM images (n = 60 microspheres). Figure 3.12 A
shows that the microspheres maintain their morphology in the CFO concentration range of 0.21.2% when 5% PLA was used. Furthermore, the microspheres appear to be well dispersed at
1.2% CFO concentration compared to other concentrations (Fig. 3.12A). When the CoFe2O4
concentration increased to > 1.6%, the microspheres were not formed and lost their morphology
(Fig. 3.12 B).

A

B

Figure 3.12-A) SEM images of CFO/PLA microspheres in different CFO concentrations 0.2-1.2 %
W/V at 5% PLA concentration B) the disruption of the morphology of microspheres at 1.6 and 2.0%
CFO concentration
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The above study was repeated with 2.5% PLA concentration by similarly varying the CFO
concentration from 0.2 to 1.2 w/v%. As shown in Figure 3.13A, the microspheres retained their
spherical morphology throughout the concentration range. Although the spheres were washed
several times with distilled water, the excess PLA was observed to aggregate and stick onto the
surface of the spheres (refer to TEM of spheres, Figure 3.3)

A

B
Mean particle diameter (µm)

14
12

2.5% PLA

10

5% PLA

8
6
4
2
0
0.2
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0.6

0.8

1.2

CFO Concentration (w/v%)

Figure 3.13-A) SEM images of CFO/PLA microspheres in different CFO concentrations of 0.2-1.0
(W/V%) at 2.5% PLA concentration and B) A plot of Mean diameter of particles measured at different
CFO concentrations of 0.2-1.2 (W/V %) at 2.5% and 5% PLA concentrations. Error bars represent
Standard deviation.
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In contrast to the effect of polymer concentration, the microsphere size significantly decreased
with an increase in CFO concentration, specifically from 0.2% up to 0.4% (Figure 3.13B).
Figure 3.13B and further ANOVA analysis (Figure 3.14) shows that apart from a small
subsequent increase after 0.4 % the increasing CFO concentration did not have an effect of the
size of the microspheres, i.e. with increasing concentration of 0.6, 0.8 and 1.2%.

Figure 3.14-Statistical ANOVA analysis using 5% PLA, *** significant difference p<0.05, NS-not
significant difference p>0.05.

49

3.3 CFO/PLA ME Microspheres for Drug Release

3.3.1 Characterization of Dexamethasone-Based microspheres
During the synthesis of Dex-loaded pure PLA or CFO/PLA microspheres, cleaning was
performed using Acetonitrile to remove excess traces of dexamethasone, which can adversely
affect the drug release analysis. SEM images (Figure 3.15) showed that microspheres were
successfully formed with the addition of dexamethasone into the medium using 5% PLA and
0.4% CFO concentration. The analysis showed that the Dex-loaded CFO/PLA microsphere
size was in the range of 5.0±1.3µm (Fig. 3.15A), whereas Dex-loaded PLA microspheres size
was 6.2±1.7µm (Fig. 3.15B)

Figure 3.15-a) SEM images of drug loaded CFO/PLA microspheres and b) Dex-PLA microspheres.

3.3.2 Drug Release Analysis
In the following sections, the percentage of drug release was calculated using equation 7,
where the initial loaded Dex concentration was 2 mg/ml (111).
𝒆𝒒 𝟕:

% 𝑇𝑜𝑡𝑎𝑙 𝐷𝑒𝑥 𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑 =

𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑡𝑜𝑡𝑎𝑙 𝐷𝑒𝑥 𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑 𝑤𝑖𝑡ℎ𝑖𝑛 𝑡𝑤𝑜 ℎ𝑜𝑢𝑟𝑠
× 100
𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑙𝑜𝑎𝑑𝑒𝑑 𝐷𝑒𝑥 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛

Note: For the following sections;
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•

Treated microspheres with magnetic nanoparticles-CFO/PLA microspheres treated
with magnetic field

•

Treated microspheres without magnetic nanoparticles- PLA microspheres treated with
magnetic field

•

Untreated microspheres with magnetic nanoparticles-CFO/PLA microspheres not
treated with magnetic field

•

Untreated microspheres without magnetic nanoparticles- PLA microspheres not
treated with magnetic field

3.3.2.1 Effect of Magnetic Nanoparticles on Release
Dex release from both PLA and CFO/PLA microspheres without applying a magnetic field was
firstly investigated over the 2-hour duration. For both types of microspheres, the Dex release
exhibited a linear profile, indicative of zero-order drug release kinetics and potentially burst
release during this time period of the measurement. Fig. 3.16 showed that the incorporation of
magnetic nanoparticles slightly increased the rate and amount of Dex release. The microspheres
with magnetic nanoparticles released a total of 2.4% Dex within 2 hours while microspheres
without magnetic particles released 1.9%Dex. The Dex releasing rates for with and without
magnetic particles are 1.83 × 10-2 and 1.53 × 10-2 min-1 respectively. However, statistical data
analysis showed no significant difference between the mean amount of drug release for PLA
and CFO/PLA microspheres without the application of magnetic field (p=0.25).
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Figure 3.16-Dexamethasone released from PLA and CFO/PLA microspheres without applying
magnetic field, within the vitro release studies in PBS (pH =7.4, temp=37 °C, n=9)

Since both type of microspheres has an equal amount of Dex loaded, it would be
expected that the CFO/PLA has a higher drug release rate due to the smaller particle diameter
compared to only pure PLA microspheres. This is because smaller polymer microspheres have
higher surface/volume ratio, which enhances the release rate under the same experimental
conditions (58). Nevertheless, no significant difference was observed between the means of the
microspheres with versus without CFO nanoparticles, suggesting that effects other than particle
size, such as the presence of CFO that may act as a barrier to Dex release, may also contribute
to (in this case offset) the rate of drug release.
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3.3.2.2 Effect of Magnetic Field on Drug Release (Without Magnetic Nanoparticles)
The effect of an applied magnetic field on Dex release was initially investigated by exposing
the microspheres to a constant 10 Oe a.c. magnetic field (f=3Hz, Vac=50 mV) over 2 hours.
Fig.3.17 showed that microspheres treated with and without a magnetic field gave a linear
response, again indicative of zero-order drug or burst release kinetics. The PLA microspheres
released a total of 1.5% and 1.9% Dex with and without an applied magnetic field, respectively,
within 2 hours and the Dex releasing rates for treated and untreated samples were 1.18 × 10-2
and 1.53 × 10-2 min-1. No significant difference (p=0.62) was observed between means during
the release period, confirming that the magnetic field had no effect on the drug release from
only PLA microspheres.
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Figure 3.17-Cumulative Dexamethasone released from PLA microspheres with and without treated
with magnetic field, within the vitro release studies in PBS (pH =7.4, temp=37 °C, n=9)
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3.3.2.3 Combined Magnetoelectric Effect of CFO Nanoparticles and Magnetic Field
To demonstrate a synergistic, or ‘magnetoelectric’, effect of combining magnetic nanoparticles
with magnetic stimulation, Figure 3.18 shows a comparison of Dex release from all the
different treated samples.
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Figure 3.18-Cumulative dexamethasone released from microspheres within the vitro release studies in
PBS (pH 7.4, temp= 37 °C, n=9), MNP-effect of magnetic nanoparticles, MF -effect of magnetic field
and MNP+MF -Combine synergistic effect

Figure 3.18 again shows the individual effect of either magnetic nanoparticle
incorporation (MNP (blue)) or magnetic field (MF (yellow)), respectively, versus the control (grey).
Dex release for combining both the magnetic nanoparticles and magnetic field (MNP+MF (red))
is also plotted to compare a synergistic effect from the magnetically stimulated CFO/PLA
microspheres. Significantly, statistical ANOVA showed a significant difference of Dex release
between the untreated CFO/PLA (MNP (blue)) and magnetically stimulated CFO/PLA sample
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(MNP+MF (red)). The microspheres released 1.0% and 2.4% of Dex from magnetically stimulated
CFO/PLA and untreated CFO/PLA samples, respectively, indicating that the combination of
both magnetic nanoparticles and magnetic field caused a significant decrease in Dex release.
In addition, the releasing rates for treated and untreated CFO/PLA samples were 0.86× 10 -2
and 1.83 × 10-2 min-1 respectively.

Figure 3.19 summarises all the data obtained for the different experimental conditions.
By considering all the observations, we can conclude 1) that magnetic stimulation of PLA
microspheres without CFO nanoparticles (yellow) does not have a significant effect on the rate
of Dex release (versus grey control). Though it is observed that their release rates show an
increasing deviation over time, particularly beyond 60 min, i.e. the release from treated PLA
microspheres decrease (yellow) while the untreated microspheres increase (grey). 2) The
addition of CFO MNP (blue) increased the rate of Dex release even without applying magnetic
field. However, it is noted that statistical significance was not observed between the values
(versus grey control). 3) Finally, a significant finding was that by applying a magnetic field to
PLA microspheres with CFO MNP the rate of Dex release significantly decreased from the onset
of the experiments.
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Figure 3.19-Cumulative dexamethasone released from CFO/PLA and PLA microspheres with and
without application of magnetic field, within the vitro release studies in PBS (pH 7.4, temp= 37 °C,
n=9).
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4. Discussion
4.1 Synthesis of Microspheres and Factors Influence on Size
Synthesis of ME core/shell spheres via emulsion techniques is a promising approach for
obtaining microspheres and nanoparticles. Before encapsulation of the magnetic nanoparticles,
they should be well-dispersed in the polymer solution. Accordingly, hydrophilic Fe3O4 and
CFO magnetic nanoparticles can be dispersed in hydrophilic polymers though less so in the
case of hydrophobic polymers. To increase hydrophobicity of these magnetic nanoparticles,
surface treatment with oleic acid and sodium dodecylsulphate (SDS) has been used (109). Yet
it is interesting to find that most of the literature reports successful synthesis of magnetoelectric
(ME) composite with only untreated magnetic nanoparticles (60, 74).
Gomez-Lopera et al. (74) and Okassa et al. (118) previously synthesized PLA ME
composite sub-micron spheres within the size range of

130-230 nm and 268-327 nm,

respectively, using double emulsion synthesis with Fe3O4 magnetic particles. However, in this
work, we were unable to synthesize ME core/shell microspheres using the double emulsion
method, as explained in section 2.2.1.1. In the previous studies (74, 118), the synthesis was
done using their own synthesized Fe3O4 magnetic particles, while we used commercially
obtained nanoparticles comprising 1% Polyvinylpyrrolidone (PVP). Thus, they were unable to
be encapsulated in the PLA and form microspheres as described earlier in section 3.1.1.
Asmatulu et al. (119) used the single emulsion synthesis approach with PLA and Fe3O4,
producing ME spheres in the range of 268-327 nm and Zhang et al. (58) produced spheres
with 0.8-2.4 µm size using the same approach. Similarly, the spheres synthesized by Correia
et al. (60) using CoFe2O4 magnetic nanoparticles obtained PLA ME spheres of 0.8-2.2 µm size,
which is smaller than those obtained in this work (3.4-4.2 µm). This microsphere size
difference can be caused by the emulsification speed which they do not specify in the literature.
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However, the major drawback of the emulsification method is the broad size distribution of
particles(120).
The particle size is a crucial factor for drug release using polymer-based microspheres.
Because of the higher surface area-to-volume ratio, smaller sized spheres show higher rate of
drug release, which decreases with increasing particle size. It is easier for the drug to interact
with solvent, as the solvent only needs to penetrate less of a distance for smaller particles (121).
In contrast, Berkland et al. (122) found that larger particles had a higher rate of polymer
degradation, eventually leading to accelerated rate of drug release. In addition, it has been
shown that particle size directly affects the drug distribution within the spheres. During
synthesis, some drugs may lose their exterior hydrophilic nature due to limited solubility of the
polymer matrix. This tends to increase the local drug concentration near the outer surface, thus
leading to non-uniform drug distribution within the sphere. Smaller particles show a more
uniform drug distribution because the drug needs to travel less distance compared to larger
microspheres. Finally, the particle size also affects the drug delivery rates via their interaction
in the body. For instance, in pulmonary-based drug delivery, larger particles can accumulate in
the respiratory tract before entering into the lungs, while smaller particles aggregate together
before entering to the target or otherwise detected and removed by phagocytosis (120). In this
thesis, we sought to investigate the effect of polymer and magnetic nanoparticle concentration
on microsphere size.

4.1.1 PLA Concentration
According to the Figure, 3.10, the microsphere size shows a positive relationship with
increasing PLA concentration. The observation may be attributed to the increase in PLA that
results in increasing viscosity of the dispersed phase, causing the emulsified droplets to
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undergo coalescence during synthesis and leading to an increase in microsphere size (123).
Likewise, Freitas et al. (124) and Dinarvand et al. (117) changed the PLA concentration in the
range of 0.05-0.15% and 2.5-4%, respectively, finding that the particle diameter increased with
higher polymer concentrations. This is further supported by studies done by Jeffery et al. (125)
and Rodrigues et al. (126) where they used Poly-lactide-co-glycolide (PLGA) and Dextran as
the polymer, respectively. Furthermore, Freitas et al. (124) found that the combination of three
parameters; PLA concentration, stirring rate and volume of the aqueous phase controlled the
particle size.

4.1.2 CFO Concentration
The results described in Figure 3.13B shows that the micro size is largest at 0.2% CFO. Beyond
this concentration, > 0.2%, there is a significant decrease in microsphere size but no further
dependence on increasing concentration is observed. Goncalves et al. (83) similarly found that
the microsphere diameter was independent of the inner CFO content. Even when the CFO
inner content was varied from 5-27%, the sphere diameter remained within the range of 3-7
µm. We effectively observed a similar result though because the CFO concentration range of
0.4-1.2% was much lower and we were able to observe a critical concentration 0.2%, where
there was an effect.
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4.2 Properties of Microspheres

4.2.1 Magnetic Properties
Similar studies done by Correia et al. (60) found that 40% of CFO nanoparticles were
encapsulated within the CFO/PLA microspheres, which is very high compared to our
maximum of 15%. The possible reason behind this variation can be the solubility of the
polymer. In this case, the previous study used PLA with molecular weights ⁓200,000 g/mol-1
whereas we used a higher molecular weight of ~ 300,000 g/mol-1, which may not disperse the
CFO nanoparticles as easily and therefore the encapsulation efficiency is higher. Studies done
by Goncalves et al. (83) using CFO/PVDF microspheres fabricated via electro spraying
demonstrated ⁓30% encapsulation efficiency. Theoretically, in chemical synthesis, CFO
nanoparticles can be sedimented in the solution whereas electro spraying is more likely to
produce a homogenous (aerosol) distribution, leading to increased encapsulation efficiency.

4.2.2 Piezoelectric Properties
Piezoelectric materials can generate an electric charge in response to an applied mechanical
stress. The (PLLA) Poly (L-lactic acid) chiral form of PLA exhibits shear piezoelectricity (127)
yet we were unable to detect any piezoelectric response in the amplitude or phase signals of
the PFM measurements. This may be due to several reasons, including that the PLA is a
polymer that exhibits shear piezoelectricity, approximately 10 pC/N (128). This
piezoelectricity is naturally inherent within their chiral structure and due to rotation of
permanent dipoles in the uniaxial oriented molecule (Fig. 4.1A). To enable a piezoresponse,
dipoles of the PLA therefore need be arranged uniaxially, as illustrated in Figure 4.1A (129).
This gives rise to electric displacement of PLA response to a mechanical stress in the directions
of d14 and d25 (Fig.4.1C). Thus, shear piezoelectricity is exhibited. In this work, it is hard to
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distinguish the direction of dipoles in a microsphere. It is expected that a response would only
be detected if measured in the corresponding direction, i.e. lateral direction for shear
displacement. Related to this, the shear piezoresponse of the microspheres may very small and
difficult to detect, A shear displacement may possibly show up in the normal direction in SSPFM yet this was evidently not the case.

(A)

(B

(C

Figure 4.1-A) Schematic diagram of PLA showing its permanent dipole direction (129) B) Illustration
of the direction of positive and negative polarity and the stress direction of d33 and C) piezoelectric
directions of drawn chiral PLLA polymer (130).

A lack of piezoresponse may also be exacerbated by the amorphous nature of the PLA, as
indicated by the absence of bands 920 and 1510 cm-1 in FTIR spectrum in Figure 3.4. For
example, most of the piezoelectric polymers, for example PVDF and PLA, show increased
piezoelectricity with a higher crystalline content (59). In addition, previous studies (83, 116)
using electrospinning or electrospraying for making PLA films and fibers enhance the polarity
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by stretching the polymer and also applying a high voltage electric field to increase the
piezoresponse. Due to the inherent piezoelectric properties of the PLA, an electrical field or
poling should not be essential to generate piezoresponse as in the case of PVDF (130). Though
Sencadas et al. (131) demonstrated piezoelectricity of PLA nanofibers by electric poling using
PFM and showed that increasing the poling voltage results in greater piezoelectric response
(Fig.4.2). In contrast to electrospinning and spraying, the emulsion technique is not likely to
induce strain on the polymer. Alternatively, the polymer cannot be stretched or ’drawn’ after
fabrication with emulsion synthesis and spheres (132, 133).

Figure 4.2-PLLA nanofibers poled at a)100 V, b)200 V and c) the measured piezoelectric response of
X at 100 V (blue) and 200 V (red) (131).
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4.3 Polymeric Microspheres for Drug Release
Polymer-based microspheres are perfect carriers for drug delivery applications due to their
biocompatibility, ease at incorporating various drugs, controlled drug delivery and release,
minimal side-effects and reduce dosage (111). These polymeric microspheres can incorporate
various biological materials used for protein therapeutics. For example, Castellanos et al. (134)
and Li et al. (135) studied PEG-PLGA microsphere systems encapsulating y-chymotrypsin and
glucose oxidase proteins. Hedley et al. (136) and Capan et al. (137) studied plasmid DNA
encapsulated PLGA microspheres for gene therapy.
Major mechanisms involved in the drug release (138) are degradation of the polymer
shell, diffusion of drug through the polymer matrix, and release via both polymer degradation
and drug diffusion (Fig. 4.3). The release rates are determined by the microsphere size,
structure; polymeric properties of molecular weight, crystallinity and copolymer ratio; and
interactions between the polymer and drug (and physical properties of the drug) (139). In
addition, factors like medium, pH and temperature of the medium also affects the drug release
rate (140).

Figure 4.3-Illustration of different drug release mechanisms from polymer-based spheres (138).
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4.3.1 Types of Drug Release Profiles
Figure 4.4 illustrates three basic drug release profiles. The type 1 represents the burst release,
the type 2 corresponds to the two-phase release, including initial burst and saturation, and the
type 3 represents three-phase release profile having initial burst, saturation and secondary burst
stages. The burst release stage can be caused by the formation of large pores in the polymer
matrix, free drug particles accumulated within microspheres, diffusion of drug particles located
on the surface or breakdown of microspheres. If the drug is hydrophilic, it can quickly diffuse
through aqueous medium and the time consuming for burst release is less compared to
hydrophobic drugs. In the saturation stage, there is slower drug release which occurs through
few pores in the highly dense polymer matrix. Finally, a secondary burst stage can occur due
to degradation and the collapse of microspheres (140).

Figure 4.4-Drug release profiles for PLA, PLGA microspheres (140).

4.3.2 Smart Release Systems
Smart release systems of hydrogels, polymeric disks, rods, pellets and microspheres are
developed to overcome the difficulties of controlled drug release associated with traditional
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drug delivery systems. To cure some diseases, it is required to maintain a constant drug
concentration, thus curtailing the burst release is required. Alternatively, the release of drugs
like antibiotics and pain killers may benefit from burst release at various time intervals,
emphasizing the importance of tailoring the release profile (120).
Core/shell microspheres are such structures used to control the rate of drug release,
particularly the development of an outer shell which is important. For example, studies done
by Huang et al. (141) using lidocaine drug found that gelatine coated on PLA/PEG
microspheres showed a significant decrease in burst release and the time duration for total
release increased. Polyethylene glycol (PEG) has higher hydration characteristics which
allows the hydrophilic lidocaine to easily dissolve and release through diffusional transport,
giving initial higher burst release of ~ 60%. The surface coating of gelatine reduces the initial
burst by 98% by formation of strong hydrogen bonding with PEG. Similarly, Chan et al. (142)
studied Docetaxel release from PLGA-Lecithin-PEG core/shell microsphere system and found
that changing the lipid or Lecithin/ polymer ratio from 0.1 to 100% reduced the Docetaxel
release rate from 50% within 20 h (Fig. 4.5). Further, they discussed that the individual
changing of PLGA or PEG surface density does not affect the releasing rate. It was suggested
that the lipid layer acts as a barrier to control drug release by keeping Docetaxel molecules in
the hydrophobic core and avoid penetration of H2O molecules in to the core.

B

A

Figure 4.5 -A) illustration of PLGA-Lecithin-PEG core/shell structure and B) Docetaxel releasing rates
with changing Lecithin/polymer ratio (142).
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In addition, studies have developed targeted drug release through a pH sensitive shell,
where the release can be tuned with pH (143). Soppimath et al. (144) studied the Doxorubicin
anticancer drug releasing rates for a folate conjugated poly(N-isopropylacrylamide-co-N,Ndimethylacrylamide-co-10-undecenoic acid) P(NIPAAm-co-DMMAm-co-UA)/cholesterol
core/shell nanoparticle system at different pH of 7.4, 6.6 and 5.0. The release rates were lower
at pH 7.4, which was 25% after 48h while the particles in medium of pH 5.0 and 6.6 released
64% and 54% after 48h, respectively, because of the deformation of the core/shell structure in
the acidic medium. In addition, the initial burst also decreased with the increasing pH.

4.3.4 Magnetically Controlled Drug Release
The drug release can be stimulated using an external magnetic field. To date most of the
research in this area is based on magnetic hydrogels (7, 145). Satarkar et al. (146) reported
magnetic hydrogel nanocomposites synthesized with Fe3O4 nanoparticles in temperature
sensitive poly(N-isopropylacrylamide) hydrogels for remotely controlled release of Vitamin
B12. They continuously applied 297 kHz high frequency with 5.3 kA/m alternating magnetic
field to hydrogel discs and found an increase in Vitamin B12 release compared to the control
without an applied magnetic field. The magnetic field caused a temperature increase within the
nanocomposite that leads to collapse of the particles and increased release of drug. Further
studies with Methylene blue instead of Vitamin B12 with the magnetic field of 10 min ON and
20 min OFF gave higher release rates in the ON mode. Similarly, Meenach et al. (147)
developed PEG based magnetic hydrogels incorporating anti-cancer drugs Methyl ether
methacrylate and Tetra(ethylene glycol) dimethacrylate (TEGDMA). These hydrogel discs
were magnetically stimulated using 297 kHz high frequency alternating magnetic field of 25
kA/m.

66

4.3.5 Magnetoelectrically Controlled Drug Release
To date polymer-based systems using magnetoelectric effects for drug release have not been
recorded, rather ceramic ME composites such as CFO/BTO have been studied (67, 99), as
described in section 1.7.1.
The drug release via ME composites occurs through the breakage of bonds with the application
of an AC magnetic field, as explained in section 1.6.1. The applied external magnetic field
induces stress within the magnetic particles which is then transferred to the ferroelectric
constitute. Then displacement of charges in the ME composite change the dipole moment and
cause the bond breakage.

4.3.6 Dexamethasone Release Study Using CFO/PLA ME Microspheres
The following section 4.3.6 discusses the ME controlled drug release using CFO/PLA polymerbased microspheres which have not yet to be described in the literature.

4.3.6.1 Effect of Magnetic Nanoparticles
The incorporation of the CFO magnetic nanoparticles reduces the microsphere size as
described in section 3.3.3.1 (Fig 3.15). Thus, a higher drug release rate from CFO/PLA
microspheres compared to PLA microspheres was reasonably expected.

However, the

presence of CFO nanoparticles in the polymer may also hinder, e.g. block, the diffusion
pathway of the Dex, resulting in an opposing decrease in release rate. Accordingly, there was
no significant difference between the release rates of CFO/PLA and PLA microspheres, as
shown in Figure 3.16, possibly suggesting the interplay of the aforementioned effect of
microsphere size versus CFO nanoparticles on diffusion.
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4.3.6.2 Effect of Magnetic Field
Figure 3.17 (section 3.3.2.2) showed that the application of a magnetic field by itself
(to pure PLA microspheres) had no significant effect on the drug release. Theoretically, when
a changing magnetic field is applied to a conducting solution, e.g. electrolyte or biological
medium, an electromotive force can be generated on the system, known as induction (148).
Related to drug release, this induction mechanism was nicely demonstrated by Gao et al. (149)
who applied a magnetic field to Dex loaded conducting polymer, polypyrrole nanofilms and
nanowires. They found that the Dex release rate significantly increased with the applied
magnetic field, explained by an induction effect that causes electrochemical redox changes in
the polypyrrole and its overall net charge that breaks the electrostatic interactions with Dex to
increase the release rate. While an induction can effect in our solution with the movement of
ions, it does not influence the Dex interaction with polymer or its diffusion.

4.3.6.3 Synergetic Effect of Magnetic Nanoparticles and Magnetic Field
While the incorporation of either magnetic nanoparticles or applied magnetic field does not
have a significant effect on the Dex release, a main finding in the thesis is that a synergistic
effect exists between the two, as given in Figure 3.18 (section 3.3.2.3). In particular, it was
observed that the application of the magnetic field to CFO/PLA microspheres reduced the total
percentage release by 1.4 %. At this stage, the release mechanism is not well understood. By
way of deduction, the role of induction, as described above, does not appear to play a significant
role given the lack of an effect in Figure 3.17. We therefore suggest that other possible
mechanisms, which are described below.
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4.3.6.4 Possible Mechanisms for Dexamethasone Releasing Rate of CFO/PLA
Microspheres
Firstly, the microsphere system initially electro-statistically equilibrates with charges of
CFO/PLA and Dex. Once the magnetic field is applied to the system, the polarity change of
the piezoelectric polymer (using the conventional theory of ME effect (Section 1.7.1)) could
break the electrostatic interactions, or hydrogen bonding between the partially charged Oδ-–Hδ+
groups of polymer and lone pairs in O atoms of the drug or vice versa. Thus, this could increase
the release of drug from the microspheres. On the other hand, if the polarization is in the
opposite direction, then it is possible that the electrostatic interactions may be stronger and the
rate of drug release is reduced due to charge leakage to the CFO, which could affect the Dex
interaction and lead to the results obtained in section 3.3.2.3 (Fig. 3.18). However, we were not
able to observe a piezoelectric response of the PLA, as described in section 3.1.4, and as such
further investigation is required to confirm the above mechanism. Furthermore, it is also
important to measure “true” ME effect whereby a change in the piezoelectric response (e.g.
PFM amplitude) is detected while applying a magnetic field (116).

According to the above mechanism, or conventional ME effect, the magnetic particles
undergo expansion and contraction (magnetostriction), which induces strain on the
piezoelectric PLA. In contrast, a second mechanism is based on the physical movement of
magnetic nanoparticles due to the applied magnetic field.

In this case, when there is a magnetic field applied to the system, the magnetic particles
physically move over some XYZ distance. This displacement of the magnetic particles then
leads to occupation of pores. Thus, the drug diffusion pathways are blocked and reduce the
releasing rates.
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5. General Conclusion
In conclusion, the project was focused on the development and characterisation of injectable
CFO/PLA microsphere systems for controlled drug delivery and release applications. I
successfully synthesized the CFO/PLA ME microspheres via W/O emulsion synthesis, with an
average particle size of 3.8±1.6 µm at 5% PLA and 0.4% CFO. Further, I demonstrated the size
of microspheres increased with increasing PLA concentration from 1% to 10%, while there is
no trend with CFO concentration increase from 0.4% to1.2%.

The CFO/PLA microspheres demonstrated their magnetic character, with separation in
solution and retentions of 8-15% CFO. However, we were not able to confirm their
piezoelectricity, thus the aim of synthesising magnetoelectric spheres was not established.

Nevertheless, the microspheres could be produced in the presence of Dexamethasone
and significantly the application of 10 Oe external alternating magnetic field to CFO/PLA
microspheres revealed a synergetic effect by causing a decrease in the Dexamethasone release.
While the investigation of the mechanism of the release was not the scope of this thesis and is
not fully understood, the ability to reduce the releasing Dexamethasone rate opens up the
possibility of modulating the release profile.
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6. Future Work
Initially, it is important to understand the mechanisms behind the drug release with the
application of a magnetic field for these ME particulates. I have discussed possible mechanisms
for drug release in the section 4.3.6.4 though they are still not well understood. However, the
mechanisms of drug release with ceramic composites like CFO/BTO is explained Nair et al.
(99), where the AZTTP drug molecules are released by the breakage of bonds with applied
magnetic field. Thus, modifying the structure of polymer and drug would possibly enable a
well-defined approach for magnetoelectric composites.
Trying different fabrication methods could be important. The fabrication using novel
technologies like coaxial 3-D printing or electrospraying would be a worthwhile approach. 3D printed polymeric composites offers many advantageous, including high precision, cost
effective and ability to generate customized shapes (Fig. 6.1) (150). Similarly, electro-spraying
allows the formation of ME microspheres with higher magnetic content encapsulated and
resulting reproducible unique size of spheres (83).

A

B

Figure 6.1- A) 3-D printed PLA scaffolds incorporating with Poly-Dopamine and Xu-Duan, a Chinese
herbal medicine (151) and B) cross section of fractured 3-D printed Carbon/PLA fiber composite (152).

Moreover, the future research could be extended to controlling drug release via ME
microspheres, which could exhibit, 1) lower initial burst release rate; it is important to treat
71

diseases requiring a continuous drug concentration over time. Thus, it would be interesting to
prepare microspheres by adding two polymeric shells instead of single shell, as demonstrated
by Kelmendi-Doko et al. (153). For example, they developed double-walled dexamethasone
encapsulated microspheres with PLLA and PLGA to control the burst release. 2) Increased
rate of drug release at specific time-points, e.g. when using antibiotics developing drug
incorporated microsphere systems that can control ‘on/off’ drug release with an external
stimulus could enable this. For example, to date, ferrogels used this on and off drug releasing
technique (154).
Specifically, for ME composite microspheres, it would be recommended to use
polymers with higher piezoelectricity, as well as having good biocompatibility and
biodegradability. Due to it toxicity, the use of CFO as magnetic component would also have to
make way for other types of magnetic nanoparticles such as Fe3O4, which is currently widely
used in biomedical applications. Having successfully demonstrated an ability to control the
release of Dex, the future research could be extended to using different type of drugs. For
example, Dex is a hydrophobic drug that does not readily dissolve in hydrophobic polymers
such as PLA. Lastly, understanding how to achieve greater magnetically controlled drug
release over longer time periods will be important. The CFO/PLA microspheres developed in
in this study could also be tested in in-vitro and in-vivo cell studies in future.
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